_______________________________________________

                       SECURITIES AND EXCHANGE COMMISSION

                             Washington, D. C. 20549

                                    FORM 10-Q


               QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF
                      THE SECURITIES EXCHANGE ACT OF 1934.

                  For the quarterly period ended April 30, 2000


     Commission File Number 001-12567

                              POSSIS MEDICAL, INC.

                          9055 Evergreen Boulevard N.W.

                        Minneapolis, Minnesota 55433-8003

                                 (763) 780-4555


     A Minnesota Corporation              IRS Employer ID No. 41-0783184

                        _________________________________


     Indicate  by check mark  whether the  Registrant  (1) has filed all reports
required to be filed by Section 13 or 15(d) of the  Securities  Exchange  Act of
1934  during  the  preceding  12 months  (or for such  shorter  period  that the
Registrant was required to file such reports),  and (2) has been subject to such
filing requirements for the past 90 days. Yes X No___

     The number of shares outstanding of the Registrant's Common Stock, $.40 par
value, as of June 1, 2000 was 16,680,706.

                        ________________________________

<PAGE>

                              POSSIS MEDICAL, INC.

                                      INDEX



                                                                       PAGE


PART I.    FINANCIAL INFORMATION

  ITEM 1.  Financial Statements

           Consolidated Balance Sheets, April 30, 2000
           and July 31, 1999.........................................     3

           Consolidated Statements of Operations for the three
           months and nine months ended April 30, 2000 and 1999......     4

           Consolidated Statements of Cash Flows for the
           nine months ended April 30, 2000 and 1999 ................     5

           Notes to Consolidated Financial Statements................     6

  ITEM 2.  Management's Discussion and Analysis of Financial
           Condition and Results of Operations.......................     7



PART II.   OTHER INFORMATION

  ITEM 6.  Exhibits and Reports on Form 8-K..........................    12

  SIGNATURES.........................................................    13

<PAGE>

                      POSSIS MEDICAL, INC. AND SUBSIDIARIES
                           CONSOLIDATED BALANCE SHEETS
                                   (UNAUDITED)

<TABLE>
<CAPTION>

ASSETS                                           April 30, 2000    July 31, 1999
<S>                                                <C>              <C>
CURRENT ASSETS:
     Cash and cash equivalents...................  $ 2,203,212      $ 9,151,004
     Marketable securities.......................   14,101,761             --
     Receivables:
        Trade (less allowances for doubtful
           accounts and returns of $640,000
           and $489,000, respectively) ..........    2,230,248        3,063,311
     Inventories:
        Parts....................................    1,585,786        1,218,910
        Work-in-progress.........................    1,484,082        1,596,313
        Finished goods...........................    1,994,888        1,556,482
     Prepaid expenses and other assets...........      135,780          247,907
                Total current assets.............   23,735,757       16,833,927
PROPERTY:
     Leasehold improvements......................    1,338,118        1,274,814
     Machinery and equipment.....................    4,682,391        4,143,032
     Assets-in-construction......................      404,586          258,114
                                                                                                                 6,425,095
5,675,960
     Less accumulated depreciation...............   (3,327,061)       2,887,025
                Property - net...................    3,098,034        2,788,935
OTHER ASSETS:
     Goodwill - net..............................      143,922          197,922
TOTAL ASSETS.....................................  $26,977,713      $19,820,784

LIABILITIES AND SHAREHOLDERS' EQUITY

CURRENT LIABILITIES:
     Trade accounts payable......................  $ 1,024,652      $   879,173
     Accrued salaries, wages, and commissions....    1,573,653        1,605,680
     Current portion of long-term debt...........       92,348           92,490
     Other liabilities...........................    1,043,033          726,940
                 Total current liabilities.......    3,733,686        3,304,283

LONG-TERM DEBT...................................       96,165           99,728
OTHER LIABILITIES................................         --            102,000


COMMITMENTS AND CONTINGENCIES

SHAREHOLDERS' EQUITY:
     Common stock - authorized 100,000,000
        shares of $.40 par value each;
        issued and outstanding, 16,680,491
        shares and 14,998,360  shares,
        respectively.............................    6,672,197        5,999,344
     Additional paid-in capital..................   74,546,140       60,608,623
     Unearned compensation ......................      (70,704)        (141,467)
     Retained deficit............................  (57,999,771)     (50,151,727)
                 Total shareholders' equity......   23,147,862       16,314,773

TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY.......  $26,977,713      $19,820,784

<FN>
See notes to consolidated financial statements.
</FN>
</TABLE>

<PAGE>

                      POSSIS MEDICAL, INC. AND SUBSIDIARIES
                      CONSOLIDATED STATEMENTS OF OPERATIONS
                                   (UNAUDITED)


<TABLE>
<CAPTION>

                                                                  For Three Months Ended             For Nine Months Ended
                                                              April 30, 2000   April 30, 1999    April 30, 2000     April 30, 1999
<S>                                                              <C>             <C>               <C>                <C>
Product sales..............................................      $ 4,472,184     $ 3,739,108       $14,110,664        $8,361,575
Cost of sales and other expenses:
     Cost of medical products..............................        2,167,251       2,388,331         6,843,468         5,809,886

     Selling, general and administrative...................        4,092,624       3,117,129        11,545,041         7,608,750
Research and development...................................        1,294,618       1,510,315         3,916,676         4,530,982
Interest...................................................            2,265          28,216             6,871           379,241
        Total cost of sales and other expenses.............        7,556,758       7,043,991        22,312,056        18,328,859


Operating loss.............................................       (3,084,574)     (3,304,883)       (8,201,392)       (9,967,284)

Interest income............................................          178,342          80,256           353,348           357,352


Net loss...................................................      $(2,906,232)    $(3,224,627)      $(7,848,044)      $(9,609,932)
Weighted average number of common
      shares outstanding...................................       16,057,405      13,909,660        15,362,701        12,852,970


Basic and dilutive net loss per common share...............         $(.18)          $(.23)            $(.51)            $(.75)



<FN>
See notes to consolidated financial statements.
</FN>
</TABLE>

<PAGE>

                      POSSIS MEDICAL, INC. AND SUBSIDIARIES
                      CONSOLIDATED STATEMENTS OF CASH FLOWS
                FOR THE NINE MONTHS ENDED APRIL 30, 2000 AND 1999
                                   (UNAUDITED)

<TABLE>
<CAPTION>
                                                        2000            1999
<S>                                                 <C>            <C>
OPERATING ACTIVITIES:
Net loss .......................................... $(7,848,044)   $ (9,609,932)
Adjustments to reconcile net loss to net
  cash used in operating activities:
(Gain) loss on asset disposal .....................      (4,718)          3,049
Depreciation.......................................     820,734         743,220
Amortization  .....................................      54,000         186,077
Stock compensation to employees and stock options
          issued to non-employees..................     169,663         263,202
(Increase) decrease in receivables.................     833,063      (1,497,989)
(Increase) decrease in inventories.................  (1,043,931)        592,167
Decrease in other assets...........................     112,127         115,383
Increase (decrease) in trade accounts payable......     145,479        (797,944)
Increase in accrued and other current liabilities..     197,947         338,216

Net cash used in operating activities..............  (6,563,680)     (9,664,551)

INVESTING ACTIVITIES:
Additions to plant and equipment...................    (780,457)       (505,157)
Proceeds from the disposal of assets...............       6,222          14,001
Purchase of marketable securities.................. (17,116,761)           --
Proceeds from maturity of marketable securities....   3,015,000            --
Net cash used in investing activities.............. (14,875,996)       (491,156)


FINANCING ACTIVITIES:
Proceeds from issuance of stock and exercise of
     options and warranties........................  14,495,589       1,240,642
Repayment of long-term debt........................      (3,705)        (12,884)
Proceeds from notes payable........................        --            21,074

Deferred debt issue costs..........................        --           (24,255)
Net cash provided by financing activities..........  14,491,884       1,224,577


DECREASE IN CASH AND CASH EQUIVALENTS .............  (6,947,792)     (8,931,130)
CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD...   9,151,004      13,841,793

CASH AND CASH EQUIVALENTS AT END OF  PERIOD........ $ 2,203,212    $  4,910,663

SUPPLEMENTAL CASH FLOW DISCLOSURE:
Interest paid...................................... $       965    $      1,674
Issuance of restricted stock.......................      59,000          20,250
Inventory transferred to fixed assets..............      23,280          32,150
Accrued payroll taxes related to restricted stock..      15,881          83,229
Conversion of subordinated debentures and accrued
     interest into common stock....................        --        12,346,174
Deferred debt issue costs and original issue
     discount netted against conversion of
     subordinated debentures.......................        --         1,371,122
Issuance of stock to settle litigation.............        --           225,000
Cancellation of restricted stock...................        --            37,934


<FN>
See notes to consolidated financial statements.
</FN>
</TABLE>

<PAGE>


                      POSSIS MEDICAL, INC. AND SUBSIDIARIES
                   NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

1.   BASIS OF PRESENTATION

     The  accompanying  unaudited  consolidated  financial  statements have been
prepared in accordance with generally accepted accounting principles for interim
financial  information and with the  instructions to Form 10-Q and Article 10 of
Regulation  S-X.  Accordingly,  they do not include all of the  information  and
footnotes  required by generally  accepted  accounting  principles  for complete
financial statements. In the opinion of management,  all adjustments (consisting
of normal recurring accruals)  considered necessary for a fair presentation have
been included.  The  accompanying  consolidated  financial  statements and notes
should be read in conjunction  with the audited  financial  statements and notes
thereto included in the Company's 1999 Annual Report.


2.   INTERIM FINANCIAL STATEMENTS

     Operating results for the three and nine month periods ended April 30, 2000
are not necessarily  indicative of the results that may be expected for the year
ending July 31, 2000.


3.    SEGMENT AND GEOGRAPHIC INFORMATION AND CONCENTRATION OF CREDIT RISK

     The  Company's   operations  are  in  one  business  segment,  the  design,
manufacture and  distribution of  cardiovascular  and vascular  medical devices.
Possis  Medical,  Inc.  evaluates  revenue  performance  based on the  worldwide
revenues   of  each  major   product   line  and   profitability   based  on  an
enterprise-wise  basis  due to  shared  infrastructures  to make  operating  and
strategic decisions.

     Total revenues by United States and  non-United  States for the nine months
ended April 30, 2000 and 1999 are as follows:

                                                        2000          1999

        United States......................         $13,837,129     $8,039,559
        Non-United States..................             273,535        322,016
        Total revenues.....................         $14,110,664     $8,361,575


4.   EARNINGS (LOSS) PER SHARE

     The  Company's  outstanding  stock  options  and  stock  warrants  were not
included in the  computation  of earnings  per share since the impact would have
been anti-dilutive because of the net loss.

<PAGE>

ITEM 2.  MANAGEMENT'S DISCUSSION AND ANALYSIS OF
         FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Results of Operations

Three and Nine Month Periods Ended April 30, 2000 and 1999

     Total product sales for the three and nine months ended April 30, 2000 were
$4,472,000 and $14,111,000,  respectively.  This was an increase of $733,000 and
$5,749,000,  respectively, as compared to the same periods in the previous year.
The main factor in the revenue  increase  was the March 1999 U.S.  Food and Drug
Administration  ("FDA")  approval to commence U.S.  marketing of the AngioJet(R)
Rheolytic(TM)  Thrombectomy  System  with  labeling  claims for removal of blood
clots in symptomatic  native coronary  arteries and coronary bypass grafts.  The
Company  recorded a net loss for the quarter  ended April 30, 2000 of $2,906,000
or $.18 per diluted share.  This compared to a net loss of  $3,225,000,  or $.23
per diluted  share,  for the quarter ended April 30, 1999.  The net loss for the
nine  months  ending  April 30,  2000 and 1999 was  $7,848,000  and  $9,610,000,
respectively.  This  resulted in a net loss per diluted  share of $.51 and $.75,
respectively.


Revenue - AngioJet System

     AngioJet  System revenue for the three and nine months ended April 30, 2000
was $4,238,000 and  $13,262,000,  respectively.  This was an increase of 28% and
69%, respectively,  over the same period year-ago periods.  Foreign sales of the
AngioJet System for the three and nine months ended April 30, 2000 were $105,000
and  $274,000,  respectively.  This  compared to foreign  sales of the  AngioJet
System of $128,000 and $322,000 for the same periods the previous year.

     As of April 30, 2000,  the Company had a total of 427 domestic  drive units
in the  field,  compared  to 239 drive  units at the end of the same  prior year
period, and 394 units as of the end of the second quarter.  During the three and
nine month periods ended April 30, 2000,  the Company sold  approximately  3,500
and 10,400 catheters and pump sets versus  approximately  2,300 and 5,700 in the
same year-ago  periods.  This was a 55% and 81% increase in unit catheter  sales
from the same  year-ago  periods.  The  average  catheter  utilization  rate per
installed  domestic drive unit was 8.3 in the third quarter,  compared to a rate
of  10.1 in the  same  prior  year  period,  and to a rate of 9.9 in the  second
quarter of fiscal 2000.  The Company sold 25 and 98 drive units during the three
and nine months ended April 30, 2000.  This compared to 40 and 95 drive units in
the same prior year-ago periods.

     Currently  the Company  lists its AngioJet  System  drive unit,  considered
capital equipment,  at $35,000 to U.S. hospitals.  The Company employs a variety
of flexible drive unit acquisition programs including outright purchase,  rental
and capital free program.  The  purchasing  cycle for the AngioJet  System drive
unit varies from  purchasing  the drive unit with no evaluation to an evaluation
period of up to six  months,  depending  on the  customer's  budget  cycle.  The
Company has recently signed contracts with two large purchasing  groups in order
to accelerate orders and marketing penetration.  These purchasing groups acquire
drive units for their member hospitals at pre-negotiated  discounts.  Due to the
continued  difficulty  in selling  capital  equipment the Company is employing a
"capital  free"  program.  This  allows  the  customer  to use the drive unit in
exchange for an increase in the catheter unit price.

<PAGE>

     The  Company  expects  U.S.  AngioJet  System  sales  to  continue  to grow
primarily through obtaining  additional FDA approved product uses,  introduction
of new  catheter  models for  existing  indications,  more face time  selling at
existing  accounts,  peer-to-peer  selling,  and  the  publication  of  clinical
performance  and cost  effectiveness  data.  The  current  sales  increases  are
believed to be generated  primarily from the FDA coronary  approval  received in
March 1999.

     In April 2000,  the Company  received FDA clearance to market the Company's
LF140  catheter  for  treating  thrombus  in  leg  (peripheral)  arteries.  This
clearance  makes  the  AngioJet   System  the  first  and  only   new-generation
thrombectomy device with FDA-approved labeling for this indication. In May 2000,
the  Company  received  FDA  clearance  to market  its new  Xpeedior  60 and 100
catheters for removing clots from dialysis access grafts. The Xpeedior catheters
are the first  catheters  marketed  by  Possis  Medical  based  its  proprietary
Cross-Stream(TM)  Technology. This exclusive technology platform intensifies the
action at the tip of the  catheter,  which  doubles  the clot  removal  rate and
triples  the  treatable  vessel  size  compared  to other  available  mechanical
thrombectomy devices on the market today. In addition,  Cross-Stream  Technology
can deal more  effectively  with "mural  thrombus,"  the older,  more  organized
material that adheres to vessel walls and can complicate patient results. In May
2000,  the  Health  Care  Financing  Administration  (HCFA)  announced  that the
AngioJet Rheolytic  Thrombectomy System has been classified as a device eligible
for  pass-through  payment in  Medicare's  new  Outpatient  Prospective  Payment
System.  Hospitals should receive  additional  reimbursement for kidney dialysis
access graft declotting  procedures  involving the AngioJet  System.  Additional
sales growth is planned due to the recent FDA actions and continued expansion of
the coronary market.

     In  October  1999,   the  Company   received  full  FDA  approval  for  its
Investigational Device Exemption (IDE) application for the clinical trial of the
AngioJet  System in the treatment of severe acute  cerebrovascular  stroke.  The
first patient was enrolled in May 2000. Due to the start of the  cerebrovascular
stroke  clinical  trial,  the  Company  has  stopped  enrolling  patients in the
clinical trial of the AngioJet  System for use in the treatment of stroke caused
by the blockage of the carotid arteries, the main vessels supplying blood to the
brain.  A total of five patients were  enrolled in the carotid  stroke  clinical
trial  (ReACT).  The  Company  believes  that the  treatment  of blood  clots in
coronary vessels,  peripheral arteries,  veins and neuro vessels are significant
worldwide marketing opportunities for the AngioJet System.


Revenue - Vascular Grafts

     Vascular  graft sales were  $234,000  and  $848,000  for the three and nine
months  ended April 30,  2000.  This  compared to $453,000  and $522,000 for the
three and nine months ended April 30, 1999. All of the vascular graft sales were
Perma-Seal(R)  Dialysis Access Grafts.  In September 1998, the Company  received
FDA marketing approval for its Perma-Seal Dialysis Access Graft, and in December
1998, the Company entered into an exclusive  worldwide  supply and  distribution
agreement  with Horizon  Medical  Products,  Inc. The first  shipment under this
agreement was made in January 1999.

     In April 1998, the Company  received  Humanitarian  Device  Exemption (HDE)
approval from the FDA,  allowing U.S.  marketing of the  Perma-Flow(R)  Coronary
Bypass Graft for  patients who require  coronary  bypass  surgery,  but who have
inadequate  blood vessels of their own for use in the surgery.  In March 1999, a
distribution  agreement  with the  Company's  independent  distributor  expired.
Currently  the  Company  is  exploring  strategic  options  relating  to  future
development and commercialization of the product.

<PAGE>

     In February 1999,  the Company  received  510(k)  clearance from the FDA to
market three expanded  poltetrafluoroethylene  (ePTFE) synthetic  grafts.  ePTFE
synthetic  grafts are the most  commonly  used  synthetic  grafts in  peripheral
vessel bypass procedures.  These products are planned to be marketed and sold by
a marketing partner or independent distributor.

     A goal of the  Company  is to  maximize  the  value of these  products  and
technologies  for  its  shareholders.  Its  strategy  is  to  seek  partners  to
distribute the products and possibly fund the graft product development program.
In  addition,  the  Company  will  continue to pursue the  possible  sale of its
vascular  graft  products  and  technologies.  While the  Company  works  toward
completing these activities, it has placed vascular graft product development on
hold.


Cost of Medical Products

     Cost of medical products decreased $221,000 and increased $1,034,000 in the
2000 three and nine month  periods,  respectively,  over the same periods in the
previous  year.  The  changes are  primarily  due to the  significant  growth in
AngioJet  System product sales and a favorable mix of coronary  catheters  sold,
partially  offset  by higher  scale-up  costs.  Medical  product  gross  margins
improved by $954,000 and $4,716,000 for the three and nine months, respectively,
over the same periods in the previous  year.  This  resulted in gross margins of
52% for the three and nine months ended April 30, 2000. This compares to 36% and
31% gross  margins  for the three and nine  months  ended  April 30,  1999.  The
Company  believes  that  manufacturing  costs per unit will be reduced and gross
margins will continue to improve as product sales and related production volumes
continue to grow and as identified product and process improvements are made.


Selling, General and Administrative Expense

     Selling,  general and administrative expenses for the three and nine months
ended April 30, 2000 increased $975,000 and $3,936,000,  respectively,  compared
to the same  year-ago  periods.  The  primary  factors are  increased  sales and
marketing  expenses  related  to  the  establishment  of a  U.S.  directs  sales
organization  to sell the AngioJet  System and expenses of marketing the product
in the United States.  Based upon early physician interest and with the AngioJet
System  receiving  FDA approval for coronary and leg artery use, the Company has
grown the U.S. sales and marketing organization from 39 employees in April 1999,
to 67 employees in April 2000. The Company expects the current level of the U.S.
sales  force will be able to grow sales and service  the  customer  base for the
Company's AngioJet System through the remainder of fiscal year 2000.


Research and Development

     Research  and  development  expenses  decreased  14% in the  three and nine
months ended April 30,  2000,  respectively,  from last year,  due mainly to the
shutdown  of  graft  product   development.   The  reduction  in  graft  product
development  was offset by an increase in  development  of new  AngioJet  System
applications.  The Company  believes that research and development  expenses for
AngioJet  System  applications  will increase as it completes the development of
its  current  products  and  invests  in  development  of  new  AngioJet  System
thrombectomy   applications  and  new  high-pressure  waterjet  technology-based
products.

<PAGE>

Interest Income

     Interest income  increased  $98,000 and decreased $4,000 in the most recent
three and nine month  periods,  respectively,  over the prior year periods.  The
increase  in the three  months  ended  April 30,  2000 was due to the March 2000
private placement offering of its common stock in the amount of $15 million. The
Company expects interest income to increase for the remainder of the fiscal year
due to the private placement offering proceeds.


Interest Expense

     Interest expense  decreased in the most recent three and nine month periods
due to the 5%  convertible  subordinated  debentures  being  converted  into the
Company's  common stock in March 1999. The Company expects  interest  expense to
stay at low levels through the remainder of the fiscal year.


Liquidity and Capital Resources

     The Company's cash, cash  equivalents and marketable  securities  totaled $
16,305,000  at April 30, 2000 versus  $9,151,000  at July 31, 1999.  The primary
factor in the improved cash position was the completion in March 2000 of the $15
million private placement offering.

     Net cash and marketable securities usage for the nine months April 30, 2000
averaged  $816,000 per month. The $6,564,000 cash used in operations in the most
recent  nine  month  was due to the  net  loss of  $7,848,000  and a  $1,044,000
increase in inventory offset by non-cash expenses of depreciation, amortization,
stock  compensation  to employees and stock options issued to  non-employees  of
$1,044,000,  a decrease in accounts  receivables  of $833,000 and an increase in
accounts payable and accrued liabilities of $343,000.

     The Company believes that product sales of the AngioJet  System,  primarily
in the U.S.,  will yield  meaningful  sales  growth going  forward.  The Company
expects the current level of the U.S. sales force will be able to grow sales and
service  the  customer  base  for the  Company's  AngioJet  System  through  the
remainder  of fiscal  year  2000.  Research  and  development  expenditures  are
expected to increase as the Company  completes  the  development  of its current
products  and  invests  in  development  of  new  AngioJet  System  thrombectomy
applications and new high-pressure waterjet  technology-based  products.  Possis
expects to report a loss for the current  fiscal  year,  which is expected to be
less than the fiscal 1999 loss. In addition, the Company expects that increasing
working capital  investments in trade receivables and inventory will be required
to support growing product sales.  The Company has no plans to raise  additional
outside capital in fiscal 2000.

<PAGE>

Forward-Looking Statements

     Management's  Discussion and Analysis of Financial Condition and Results of
Operations,  including the discussion  regarding Year 2000  compliance,  contain
certain  "forward-looking  statements"  as  defined  in the  Private  Securities
Litigation  Reform Act of 1995.  Such  statements  relating to future events and
financial  performance,  including the  submission of  applications  to the FDA,
anticipated  FDA  approvals,  the timing of FDA  approvals,  revenue and expense
levels, profitability and future capital requirements, and the timing and method
of raising additional capital, are forward-looking statements that involve risks
and uncertainties, including the Company's ability to meet its timetable for FDA
submissions,  the review time and process at the FDA, anticipated  reimbursement
for the use of its  products  by its  customers,  results  of  clinical  trials,
changes  in  the  Company's  marketing  strategies,  the  Company's  ability  to
establish  product  distribution  channels,  changes in  manufacturing  methods,
market  acceptance  of the  AngioJet  System,  changes  in the levels of capital
expenditures  by hospitals,  the levels of sales of the Company's  products that
can be achieved,  ability to raise additional  capital and other risks set forth
in the cautionary  statements  included in Exhibit 99 to the Company's report on
Form  S-3  dated  April  17,  2000,  filed  with  the  Securities  and  Exchange
Commission.



ITEM 3.  QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

     The Company  invests  its excess cash in money  market  mutual  funds.  The
market risk on such investments is minimal.

     The product sales for the Company's foreign  subsidiary are in U.S. Dollars
("USD").  At the end of April  2000,  the  amount of  currency  held in  foreign
exchange was approximately  $1,000 USD. The market risk on the Company's foreign
subsidiary operations is minimal.

     At April 30, 2000, all of the Company's  outstanding long-term debt carries
interest at a fixed  rate.  There is no  material  market  risk  relating to the
Company's long-term debt.

<PAGE>

Part II.  OTHER INFORMATION

ITEM 6.  Exhibits and Reports on Form 8-K

     (a)  Exhibits

     Certain of the following  exhibits are incorporated by reference from prior
filings.  The form with which each  exhibit was filed and the date of filing are
indicated below.

 Exhibit     Form       Date Filed                       Description

   3.1       10-K     Fiscal year ended         Articles of incorporation as
                      July 31, 1994             amended and restated to date.

   3.2       10-K     Fiscal Year ended         Bylaws as amended and
                      July 31, 1999             restated to date.

   27                                           Financial data schedule

   99        S-3      April 17, 2000            Investment Risk Factors



     (b) Reports on Form 8-K

     During the quarter ended April 30, 2000, the Company filed a report on Form
8-K dated March 3, 2000 reporting under Item 5 that the Company had entered into
a Private Placement Agreement.

<PAGE>



SIGNATURES

     Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned thereunto duly authorized.


                                        POSSIS MEDICAL, INC.


DATE: June 7, 2000                 BY:  /s/   Robert G. Dutcher
                                        ROBERT G. DUTCHER
                                        President, Chief Executive Officer
                                        and Principal Finance Officer